Retrospective study of salazosulfapyridine in eight patients with rheumatoid arthritis on hemodialysis

References

• Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev. 1981;3:27–44.
   PubMed Web of Science ®Google Scholar
• Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16(5):585–91.
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002;46(2):328–46.
   PubMedGoogle Scholar
• Svartz N. The treatment of rheumatoid polyarthritis with acid azo compounds. Rheumatism. 1948;4(1):180–5.
   PubMedGoogle Scholar
• McConkey B, Amos RS, Durham S, Forster PJ, Hubball S, Walsh L. Sulfasalazine in rheumatoid arthritis. Br Med J. 1980; 280(6212):442–4.
   PubMedGoogle Scholar
• Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J. 1983;287(6399):1102–4.
   PubMedGoogle Scholar
• Nishioka K, Nobunaga M, Sakuma A. Comparison of sulphasalazine and placebo in a randomized, double-blind controlled dose-finding study in patients with rheumatoid arthritis (in Japanese). Ryumachi (Jpn J Rhematol). 1991;31(3):327–45.
   PubMedGoogle Scholar
• RA research committee of Japanese Ministry of Health, Labour and Welfare. The manual of diagnosis and treatment guidelines under the principle of EBM in rheumatoid arthritis (in Japanese). Tokyo: Japan Rheumatism Foundation; 2004.
   Google Scholar
• Taggart AJ, Neumann VC, Hill J, Astbury C, Le Gallez P, Dixon JS. 5-aminosalicylic acid or sulphapyridine which is the active moiety or sulphasalazine in rheumatoid arthritis. Drugs. 1986;32(Suppl 1):27–34.
   PubMedGoogle Scholar
• Hirohata S, Ohshima N, Yanagida T, Aramaki K. Regulation of human B cell function by sulfasalazine and its metabolites. Int Immunophamacol. 2002;2(5):631–40.
   PubMedGoogle Scholar
• Matasic R, Dietz AB, Vuc-Pavlovic S. Maturation of human dendritic cells as sulfasalazine target. Croat Med J. 2001;42(4):440–5.
   PubMedGoogle Scholar
• Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and anti-inflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kB, osteoprotegerin, and receptor activator of nuclear factor kB ligand. Arthritis Rheum. 2004;50(12):3831–43.
   PubMedGoogle Scholar
• Akiyama Y, Fujimaki T, Sakurai Y. Pharmacokinetics of salazosulfapyridine in a hemodialysis patient (in Japanese). Ryumachi (Jpn J Rheumatol). 2003;43(3):569–76.
   PubMedGoogle Scholar
• Uchida E, Kai K, Kobayashi S, Oguchi K, Miyazaki Y, Yasuhara H. A study of pharmacokinetics and safety of salazosulfapyridine enteric coated tablet (PJ-306) in healthy Japanese subjects (in Japanese). Jpn J Clin Pharmacol Ther. 1990;21(2):377–89.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Tsukada Y, Murayama H, Takahashi S, Morita S. A case of ulcerative colitis complicating chronic hemodialysis (in Japanese). Endoscopic Forum Dig Dis. 1988;4(2):372–6.
   Google Scholar
• Isami Y, Okuda M, Ikeda H, Okamoto M, Toyoda T, Ikuma T, et al. Two cases of colitis in hemodialysis patients (in Japanese). Jpn Soc Dial Ther. 1993;26(12):1795–800.
   Google Scholar
• Mathueu A, Pala R, Altieri P, Balestrieri A. Oral chrysotherapy in a hemodialyzed rheumatoid patient (letters). J Rheumatol. 1985;12(2):380–1.
   PubMedGoogle Scholar
• Graninger W, Seidl G, Kovarik J, Pinggera W, Smolen JS. Oral gold therapy in a patient with rheumatoid arthritis and preexisting uremia. Arthritis Rheum. 1985;28(6):710–2.
   PubMedGoogle Scholar
• Ueda T, Tateishi H, Yoh K, Maruo S. Rheumatoid arthritis that occurred during hemodialysis. Clin Rheumatol. 1990;3:321–4.
   Google Scholar
• Matthey F, Perrett D, Greenwood RN, Baker LR. The use of D-penicillamine in patients with rheumatoid arthritis undergoing hemodialysis. Clin Nephrol. 1986;25(5):268–71.
   PubMedGoogle Scholar
• Kaizu K, Komine N, Uriu K, Ikeda M, Hashimoto O, Eto S. Bucillamine may be an effective anti-rheumatic drug in patients with end-stage renal disease - A case report - (in Japanese). Jpn Soc Dial Ther. 1994;27(12):1505–10.
   Google Scholar
• Nakayama K. Administration of mizoribine in patients with rheumatoid arthritis undergoing hemodialysis (in Japanese). J Miyazaki Med Assoc. 1994;18:203–9.
   Google Scholar
• Saisho K, Taniguchi H, Yoshimatsu N, Hanabusa A. Use of mizoribine in patients with rheumatoid arthritis complicated by renal dysfunction (in Japanese). Kyusyu Riumachi. 1998;17:69–73.
   Google Scholar
• Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002; 36(1):75–7.
   PubMedGoogle Scholar
• Iwamoto M, Homma S, Asano Y, Minota S. Administration of leflunomide to a patient with rheumatoid arthritis on hemodialysis. Scand J Rheumatol. 2005;34(5):410–11.
   PubMedGoogle Scholar
• Yamashita M, Natsumeda M, Takasugi K, Ueno A, Ezawa K, Ezawa K. Efficacy and safety of tacrolimus treatment for rheumatoid arthritis patients undergoing hemodialysis. Mod Rheumatol. 2008;18(3): 296–300.
   PubMedGoogle Scholar
• Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet. 1993;25(5):392–407.
   PubMedGoogle Scholar
• Smedegård G, Björk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol. 1995;34(Suppl 2):7–15.
   PubMedGoogle Scholar
• Rains CP, Noble S, Faulds D. Sulphasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 1995;50(1):137–56.
   PubMedGoogle Scholar
• Taggart AJ, McDermott BJ, Roberts SD. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis. Clin Pharmacokinet. 1992;23(4):311–20.
   PubMedGoogle Scholar
• Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985;10(4):285–302.
   PubMedGoogle Scholar
• Pullar T, Hunter JA, Capell HA. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy. Br J Rheumatol. 1985;24(3):269–76.
   PubMedGoogle Scholar
• Inoue M, Imai Y, Yoshida I, Yoshida N. A study of the pharmacokinetics of salazopyrin in patients with ulcerative colitis (in Japanese). Annual Report of the Ministry of Health and Welfare Refractory Inflammatory Bowel Diseases Research Committee 1979. 1980:90–6.
   Google Scholar
• Inami Y, Yamaji K, Sato M, Gohda T, Io H, Nawata M, et al. Effects of dialysis on the pharmacokinetics of salazosulfapyridine. Rheumatol Int. 2013;33(2):535–9.
   PubMedGoogle Scholar